Citations

Clear

40 citation(s) found for "Johnson, Christopher".

Unintentional Weight Loss Does Not Predict Poor Outcomes in Zenker Diverticulum
Allen, Jacqueline , Belafsky, Peter C., deSilva, Brad W. , Dhar, Shumon I. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Gardner, Glendon M., Johnson, Christopher, Kasperbauer, Jan L. , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L., Matrka, Laura , Piraka, Cyrus, Ramaswamy, Apoorva, Rosen, Clark A. , Sibley, Haley , Wright, Carter, Yang, Z. Mike, Young, VyVy N. , Postma, Gregory, Howell, Rebecca J. , Allen, Jacqui , Amin, Milan R , Bayan, Semirra L. , deSilva, Brad , Dhar, Shumon I , Ekbom, Dale , Fritz, Mark , Kasperbauer, Jan , Krekeler, Brittany N , Kuhn, Maggie , Ma, Yue , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Sibley, Haley C , Tabangin, Meredith , Young, Vyvy , Howell, Rebecca , Schuman, Ari D. , Altaye, Mekibib , Belafsky, Peter C. , Gardner, Glendon M., Guardiani, Elizabeth , Madden, Lyndsay L. , Mayerhoff, Ross , Piraka, Cyrus , Ramaswamy, Apoorva Tewari , Tabangin, Meredith E. , Postma, Gregory

Mayo Clinic

The Laryngoscope | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70734 | PMID 42470432 Get It

ABSTRACT Objective Weight loss is frequently considered a cardinal presenting symptom for patients with Zenker diverticulum (ZD). We hypothesized that weight loss in patients with cricopharyngeal muscle dysfunction (CPMD), with or without diverticula, was associated with the length of symptoms and size of diverticulum. Methods Prospective, multicenter observational study of CPMD patients with and without diverticula reporting unintentional weight loss (+WL) or no weight loss (−WL) prior to enrollment in the Prospective Outcomes of Cricopharyngeal Hypertonicity (POuCH) database. Complications and symptom response using a patient reported outcome measure, the Eating Assessment Tool (EAT‐10), were compared. Results Of 427 patients, 101 (23.6%) were +WL. Median weight loss was 14 pounds (interquartile range [IQR] 10–25). +WL cohort had a mean age of 71.5 (standard deviation [SD] 11.5) vs. 67.9 in −WL (SD 11.6, p = 0.007). Mean preoperative EAT‐10 score was 24.7 in +WL (SD 9.7) and 14.8 in −WL (SD 8.8, p < 0.0001). Higher preoperative weight loss was associated with higher preoperative EAT‐10 ( p < 0.0001, Spearman's ρ = 0.43). Size of diverticulum was associated with WL ( p = 0.003), but weight loss was highest in both large diverticula and CP bars. Duration of symptoms was not associated with weight loss ( p = 0.30). Postoperative complications in +WL and −WL patients were similar ( p = 0.78). Conclusion Unintentional weight loss is common with ZD. Patients with worse dysphagia are more likely to have more weight loss. Weight loss does not increase with the size of the diverticulum or length of symptoms. Surgery has a similar safety profile with greater improvement in dysphagia in patients reporting weight loss. Level of Evidence 3.
Multiomics alterations associated with tolerance and response to simulated progressive hemorrhage in healthy adult humans
Misganaw, Burook , Muhie, Seid , Gautam, Aarti , Miller, Stacy-Ann, Rosales, I. C. Bonilla, Dimitrov, George I., Sowe, Bintu, Johnson, Christopher P., Roberts, Shelly K., Regimbal, Riley J. , Wiggins, Chad C. , CONVERTINO, V, Joyner, Michael J , Curry, Timothy B. , Hammamieh, Rasha , Wiggins, Chad C , Gautam, Aarti, Miller, Stacy‐Ann , Dimitrov, George I., Johnson, Christopher P., Joyner, Michael J. , Convertino, Víctor A.

Mayo Clinic

Physiological Genomics | January 7, 2026 | Volume: 58 | Issue: 2 | Pages: 102-114

10.1152/physiolgenomics.00253.2025 | PMID 41494644 Get It

This study investigated the first multiomics data for association with tolerance to central hypovolemia in humans. Analyzing gene expression, proteins, and genetic variants in individuals with high and low tolerance to simulated hemorrhage, the findings show that severe blood loss causes widespread transcriptional changes, including the activation of innate immune system pathways and inhibition of gas transport processes. This research can help identify molecular factors that influence individuals’ tolerance levels for progressive blood loss.
Prevalence and demographics of autoimmune hemolytic anemia in the United States
Knoll, Christopher , Jackson, Louis , Choudhry, Zia , Shah, Surbhi , Krumme, Alexis A. , Godby, Richard , Blacketer, Clair

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6239-6239

10.1182/blood-2025-6239 Get It

Abstract Background: Autoimmune hemolytic anemia (AIHA) is a condition in which the immune system erroneously attacks and damages red blood cells. While the epidemiology of AIHA has been examined in various European and Asian nations (Hansen 2020; Kao 2025), there is limited data available from the United States (US). Using US insurance claims data, this research aimed to determine the prevalence and demographic characteristics of AIHA over a five-year span. Methods: Five databases were used: Merative MarketScan Commercial Claims and Encounters; Optum's de-identified Clinformatics® Data Mart Database; Closed and Open claims sourced through HealthVerity; Merative MarketScan Medicare Supplemental Database; Merative MarketScan Multi-State Medicaid. AIHA was defined by ICD-10 diagnosis codes D59.1x in a given calendar year and a second code within 365 days prior. Annual prevalence in years 2019 – 2023 was calculated among people with insurance enrollment for at least 6 months in the calendar year. Annual prevalence was stratified by age group, sex, and prescription fill for an AIHA-related treatment (systemic steroids, immunosuppressants [azathioprine, mycophenolate, cyclosporin, cyclophosphamide, danazol, bortezomib, rituximab], splenectomy) in the calendar year. Extrapolation of prevalence rates for commercial and government assistance insurance to the US population for 2023 was implemented by age and sex-standardization to the US Census population. For data sources that included both commercial and government assistance insurance, patients aged &lt;65 years were analyzed as commercial insurance and aged ≥65 years as government assistance. Results: AIHA prevalence in 2023 across databases ranged from 2.7 to 4.3 per 100,000 for ages &lt;18 years; 4.2 to 9.4 per 100,000 for ages 18 – 34 years; 8.2 to 11.8 per 100,000 for ages 35 – 49 years; 15.4 to 23.9 per 100,000 for ages 50 – 64 years; 26.6 to 37.0 per 100,000 for ages 65 – 74 years; and 30.6 to 61.2 per 100,000 for age 75 years and older. Across databases and over time, the proportion of AIHA patients that were female was 55% – 67%. Across all databases, in year 2023, half (44% - 55%) of patients received any AIHA-related treatment, out of which one third (26%-34%) received systemic steroids, less than one quarter (9% – 17%) received rituximab, and one third (25% – 31%) received a different immunosuppressant. Compared to patients with commercial insurance, Medicaid-insured patients had lower AIHA-related treatment utilization, whereas Medicare-insured patients had higher utilization. Within age group and sex and by insurance type, low and high estimates of prevalence were used to define a range of prevalence. After standardization to the 2023 US Census population, the estimated prevalence in 2023 ranged from 38,459 to 57,235 patients diagnosed with AIHA, corresponding to prevalence rates of 11.6 to 17.3 per 100,000. This marked an increase from 2019 US Census-standardized estimates of 32,777 to 48,482, with corresponding prevalence rates of 10.1 to 14.9 per 100,000. Discussion: AIHA prevalence was higher in older age groups, with a peak prevalence in ages 65 and older. Prevalence increased approximately 15% over a 5-year interval and was notably higher in patients with commercial health insurance compared to government insurance programs, which may in part be due to the older age of the Medicare population. Fewer than half of patients received an AIHA-related treatment in 2023, which could reflect heterogeneity in disease severity necessitating treatment, in addition to the relapse-remitting nature of AIHA whereby patients experience remission for periods of time. Additionally, insurance claims do not specify an indication for treatment nor a reason for discontinuation; some treatments could have been prescribed for an underlying condition contributing to AIHA. Finally, prevalence extrapolation assumes Americans without health insurance are diagnosed with AIHA at the same rate as those with insurance, which may slightly overestimate the total number of diagnosed patients.Conclusion: AIHA prevalence in this study was consistent with estimates from European countries and has been increasing in recent years, providing evidence of consistent disease epidemiology across several geographies.
Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)
Efebera, Yvonne A. , Wechalekar, Ashutosh , Grogan, Martha, Huart, Antoine , Rosenzweig, Michael L., Blue, Brandon , Jamal, Faizi , Pericone, Christopher D. , Vasey, Sandra Y., Chen, Yuping , Loi, Matteo, Tran, NamPhuong, Sanchorawala, Vaishali , Minnema, Monique C , Dispenzieri, Angela , Wechalekar, Ashutosh D. , Grogan, Martha , Rosenzweig, Michael, Kastritis, Efstathios

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 691-691

10.1182/blood-2025-691 Get It

Abstract Introduction AL amyloidosis is a rare disorder caused by amyloid fibrils produced by clonal plasma cells, leading to serious organ dysfunction. Cardiac involvement is a major risk factor for poor survival. CD38-binding Daratumumab (D) targets plasma cells and, with bortezomib, cyclophosphamide and dexamethasone (VCd) is the only approved regimen for newly diagnosed AL amyloidosis. The ANDROMEDA phase 3 study showed significant improvements in hematologic responses, major organ deterioration progression free survival and overall survival, compared with VCd alone. The AQUARIUS study (NCT05250973) evaluated cardiac safety of different D-VCd schedules and potential cardiac toxicity mitigation strategies. Methods This multicenter, open-label, phase 2 study enrolled 151 newly diagnosed AL amyloidosis patients at 37 sites in 10 countries. Patients enrolled in either Cohort 1 (n=120, cardiac involvement [Mayo 2004 stage II/IIIA], randomized 2:1 to receive D + immediate VCd or D + deferred VCd) or Cohort 2 (n=31, racial or ethnic minorities with ≥1 any organ involvement, treated with D + immediate VCd). Immediate VCd began on Cycle 1, deferred VCd on Cycle 4. The primary safety endpoint was the incidence of cardiac treatment emergent adverse events (TEAEs). Cardiac assessments included HS TroponinT, NT-proBNP, echocardiogram (ECHO), ECG, NYHA, and the 6-minute walk test (6MWT). Clinical cardiac signs and symptoms (S&S) were assessed at baseline and monthly. Selected, clinically relevant grade ≥3 and/or serious cardiac TEAEs were defined as Major Cardiac TEAE and were assessed by an independent adjudication committee for causality. Patients were followed for 12 treatment cycles or 12 months from first dose (if treatment discontinued prior to 12 cycles). Results 142 patients from both cohorts had cardiac involvement and received at least one dose of D + immediate VCd (n=103) or D + deferred VCd (n=39). Baseline characteristics were balanced between the two groups, including Mayo 2004 stage (IIIa: immediate VCd, 35.0%; deferred VCd, 35.9%; II: immediate VCd, 62.1%; deferred VCd, 53.8%). Treatment duration (median: 10.4 months) and proportion completing ≥10 cycles (79% vs 85%) were similar. Serious cardiac TEAEs occurred at similar rates across groups (immediate VCd, 7.8%; deferred VCd, 7.7%). The most common serious cardiac TEAE (MedDRA term) was cardiac failure (immediate VCd, 5.8%; deferred VCd, 2.6%). Two deaths occurred within 60 days of first study treatment, both were in the immediate VCd group, cardiac-related and unrelated to treatment. The immediate VCd group had fewer cardiac TEAEs overall (48.5% vs 61.5%) but experienced them more frequently during Cycles 1-3 than deferred VCd (35.9% vs 28.2%). This trend reversed for Cycles 4-6 (immediate VCd, 17.7%; deferred VCd, 28.9%). Cardiac TEAEs were low for both groups for Cycles 7-9 (immediate VCd, 9.3%; deferred VCd, 12.1%) and Cycles 10-12 (immediate VCd, 7.4%; deferred VCd, 12.1%). Levels of NT-proBNP, HS troponin T, the 6MWT, and overall cardiac S&S improved similarly for both treatment groups. Rate of cardiac TEAEs of any grade was similar for Mayo stage III patients in the two groups (immediate VCd, 73.0%; deferred VCd, 68.8%) whereas for Mayo stage II patients the incidence was higher in the deferred group (35.9% vs 57.1%). Twenty patients (Immediate VCd, 13; deferred VCd, 7) experienced 30 Major Cardiac TEAEs (selected grade ≥3 and/or serious). Adjudicators attributed 28 events primarily to amyloid cardiomyopathy and 2 events primarily to treatment. These 20 patients had higher baseline Mayo stage (IIIa: 70% vs 29.5%) than the remaining patients (n=122), higher baseline median NT-proBNP (4862 ng/L vs 1723 ng/L) and overall S&S score (7.5 vs 4.0). Several ECHO measures were worse at baseline in these 20 patients (notably, median GLS: -8.8% vs -13.7% and E prime lateral: 4.4 cm/s vs 6.1 cm/s) as was 6MWT (median distance: 319 m vs 363 m). Complete Response (CR) rates were similar in both groups: immediate VCd, 62.1%; deferred VCd, 59.0%. Median time to CR was 64 days for the immediate VCd group and 113 days for the deferred VCd group. Conclusion The D-VCd regimen (immediate or deferred) had a manageable safety profile consistent with previous studies. Cardiac TEAEs were similar between regimens, and their emergence correlated with the start of VCd. Major cardiac events were associated with underlying disease and baseline risk factors that are quantifiable and monitorable.
Multiplexed Assays of Variant Effect and Automated Patch Clamping Improve KCNH2 -LQTS Variant Classification and Cardiac Event Risk Stratification
O’Neill, Matthew J. , Ng, Chai‐Ann , Aizawa, Takanori , Sala, Luca , Bains, Sahej , Winbo, Annika , Ullah, Rizwan , Shen, Qianyi, Tan, Chek-Ying, Kozek, Krystian A. , Vanags, Loren , Mitchell, Devyn , Shen, Alex , Kashiwa, Asami , Musu, Giulia , Bos, J. Martijn , Giudicessi, John R. , Bledsoe, Xavier , Gamazon, Eric R. , Glazer, Andrew M. , Roden, Dan M. , Stiles, Rachael, Agee, Taylor , Johnson, Christopher N. , Ackerman, Michael J. , Ohno, Seiko , Vandenberg, Jamie I. , Kroncke, Brett M. , Kozek, Krystian , Mitchell, Devyn W , Wada, Yuko , Kashiwa, Asami , Crotti, Lia , Dagradi, Federica , Spazzolini, Carla , Neves, Raquel Almeida Lopes , Bos, Johan M , Giudicessi, J R , Bledsoe, Xavier , Lancaster, Megan C , Glazer, Andrew M , Knollmann, Bjorn C , Salem, Joe-Elie , Earle, Nikki , Agee, Taylor , Johnson, Christopher N , Horie, Minoru , Skinner, Jonathan R , Ackerman, Michael J , Schwartz, Peter J. , Ohno, Seiko , Vandenberg, Jamie I , Sala, Luca , Bains, Sahej , Wada, Yuko , Dagradi, Federica , Spazzolini, Carla , Neves, Raquel , Roden, Dan M. , Weile, Jochen , Roth, Frederick P. , Salem, Joe‐Elie , Skinner, Jonathan R.

Mayo Clinic

Circulation | September 24, 2024 | Volume: 150 | Issue: 23 | Pages: 1869-1881

10.1161/circulationaha.124.069828 | PMID 39315434 Get It

BACKGROUND: Long QT syndrome is a lethal arrhythmia syndrome, frequently caused by rare loss-of-function variants in the potassium channel encoded by KCNH2 . Variant classification is difficult, often because of lack of functional data. Moreover, variant-based risk stratification is also complicated by heterogenous clinical data and incomplete penetrance. Here we sought to test whether variant-specific information, primarily from high-throughput functional assays, could improve both classification and cardiac event risk stratification in a large, harmonized cohort of KCNH2 missense variant heterozygotes. METHODS: We quantified cell-surface trafficking of 18 796 variants in KCNH2 using a multiplexed assay of variant effect (MAVE). We recorded KCNH2 current density for 533 variants by automated patch clamping. We calibrated the strength of evidence of MAVE data according to ClinGen guidelines. We deeply phenotyped 1458 patients with KCNH2 missense variants, including QTc, cardiac event history, and mortality. We correlated variant functional data and Bayesian long QT syndrome penetrance estimates with cohort phenotypes and assessed hazard ratios for cardiac events. RESULTS: Variant MAVE trafficking scores and automated patch clamping peak tail currents were highly correlated (Spearman rank-order ρ=0.69; n=433). The MAVE data were found to provide up to pathogenic very strong evidence for severe loss-of-function variants. In the cohort, both functional assays and Bayesian long QT syndrome penetrance estimates were significantly predictive of cardiac events when independently modeled with patient sex and corrected QT interval (QTc); however, MAVE data became nonsignificant when peak tail current and penetrance estimates were also available. The area under the receiver operator characteristic curve for 20-year event outcomes based on patient-specific sex and QTc (area under the curve, 0.80 [0.76–0.83]) was improved with prospectively available penetrance scores conditioned on MAVE (area under the curve, 0.86 [0.83–0.89]) or attainable automated patch clamping peak tail current data (area under the curve, 0.84 [0.81–0.88]). CONCLUSIONS: High-throughput KCNH2 variant MAVE data meaningfully contribute to variant classification at scale, whereas long QT syndrome penetrance estimates and automated patch clamping peak tail current measurements meaningfully contribute to risk stratification of cardiac events in patients with heterozygous KCNH2 missense variants.
Surgical Nonresponders in Zenker Diverticulum and Lower Esophageal Pathology (POUCH Collaborative)
Brown, Johnathan , McCoy, Nicole, Allen, Jacqui , Altaye, Mekibib , Bayan, Semirra L. , Belafsky, Peter C. , deSilva, Brad W. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Johnson, Christopher , Kasperbauer, Jan L. , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Piraka, Cyrus , Rosen, Clark A. , Wahab, Shaun A. , Wilson, Keith , Wright, Carter , Young, VyVy N. , Postma, Gregory N. , Howell, Rebecca J. , Bayan, Semirra, deSilva, Brad , Ekbom, Dale , Fritz, Mark , Giliberto, John Paul , Kasperbauer, Jan , Krekeler, Brittany N , Kuhn, Maggie , Ma, Yue , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Tabangin, Meredith , Young, Vyvy , Howell, Rebecca , Bayan, Semirra , Amin, Milan R , Dion, Gregory R. , Giliberto, John Paul , Guardiani, Elizabeth , Kwak, Paul E. , Mayerhoff, Ross , Tabangin, Meredith E. , Wilson, Keith, Wright, Carter

Mayo Clinic

The Laryngoscope | July 9, 2024 | Volume: 134 | Issue: 12 | Pages: 4897-4902

10.1002/lary.31619 | PMID 38979706 Get It

ObjectiveTo identify characteristics of patients who have poor improvement in symptoms following surgical management of Zenker Diverticulum (ZD).MethodsProspective, multicenter cohort study of all individuals enrolled in the Prospective OUtcomes of Cricopharyngeus Hypertonicity (POUCH) Collaborative who underwent surgical repair of ZD between August 2017 and January 2024. Patient demographics, esophagrams, and the 10‐item Eating Assessment Tool (EAT‐10) pre‐ and post‐procedure were obtained from a REDCap database. t‐tests, Wilcoxon rank sum tests, Chi‐square or Fisher's exact tests were used to compare the characteristics. Patients with <50% improvement in their EAT‐10 scores were deemed surgical nonresponders (SNRs). Those with ≥50% improvement in their EAT‐10 scores were deemed surgical responders (SRs).ResultsA total of 184 patients were prospectively followed after undergoing either open or endoscopic surgical management. Twenty‐two patients (12%) were deemed SNRs. Preoperative presence of a hiatal hernia was statistically significant characteristic between the SNRs (63.6%) and SRs (32.1%) (p = 0.004). Size of the ZD and history of previous ZD surgery was not a significant characteristic. The length of stay and complication rate were not statistically different between the groups.ConclusionCoexistent esophageal pathology may lead to poor symptomatic improvement following ZD surgery. Preoperative workup of other esophageal disorders is recommended to detect likely SNRs. For SNRs, further esophageal workup may be necessary to evaluate for other esophageal causes related to poor symptomatic improvement following ZD surgery.Level of Evidence3 Laryngoscope, 134:4897–4902, 2024
Postoperative Care of Zenker Diverticula: Contemporary Perspective from the Prospective OUtcomes Cricopharyngeaus Hypertonicity (POUCH) Collaborative
McKeon, Mallory , McCoy, Nicole, Johnson, Christopher , Allen, Jacqui , Altaye, Mekibib , Bayan, Semirra L. , Belafsky, Peter C. , deSilva, Brad W. , Dion, Gregory R. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Kasperbauer, Jan L. , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Mayerhoff, Ross , Piraka, Cyrus , Rosen, Clark A. , Wahab, Shaun A. , Wilson, Keith , Wright, Carter , Young, VyVy N. , Postma, Gregory N. , Howell, Rebecca J. , Bayan, Semirra, Belafsky, Peter , deSilva, Brad , Dion, Greg , Ekbom, Dale , Friedman, Aaron D , Fritz, Mark , Giliberto, John Paul , Kasperbauer, Jan , Krekeler, Brittany N , Kuhn, Maggie , Ma, Yue , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Tabangin, Meredith , Young, Vyvy , Howell, Rebecca , Bayan, Semirra , Amin, Milan R , Giliberto, John Paul , Guardiani, Elizabeth , Kwak, Paul E. , Tabangin, Meredith E. , Wilson, Keith, Wright, Carter

Mayo Clinic

The Laryngoscope | December 26, 2023 | Volume: 134 | Issue: 6 | Pages: 2678-2683

10.1002/lary.31226 | PMID 38146791 Get It

Objectives The aim of the study was to identify trends in postoperative management of persons undergoing surgery for Zenker diverticula (ZD) by evaluating length of stay (LOS), diet on discharge, and imaging with or without surgical complication. Methods Prospectively enrolled adult patients with cricopharyngeal muscle dysfunction with diverticula undergoing surgery from August 1, 2017 to February 1, 2023 were included. Data were extracted from a multi‐institutional REDCap database, summarizing means, medians, percentages, and frequencies. Fisher's exact or chi squared analyses were utilized, as appropriate, to compare subsets of data. Descriptive analysis assessed differences in clinical course and the relationship to postoperative management. Results There were 298 patients with a mean (standard deviation) age of 71.8 (11.2) years and 60% male. Endoscopic surgery was performed in 79.5% (237/298) of patients versus 20.5% (61/298) open surgery. Sixty patients (20.1%) received postoperative imaging, with four leaks identified. Complications were identified in 9.4% of cases ( n = 29 complications in 28 patients), more commonly in open surgery. Most (81.2%) patients were discharged within 23 h. About half of patients (49%) were discharged from the hospital on a pureed/liquid diet; 36% had been advanced to a soft diet. In patients without complications, LOS was significantly longer following open cases ( p = 0.002); postoperative diet was not different between open and endoscopic ( p = 0.26). Conclusions Overall, most patients are discharged within 23 h without imaging. However, LOS was affected by surgical approach. Postoperative complications are different in endoscopic versus open surgery. Complications with either approach were associated with prolonged LOS, need for imaging, and diet restriction. Level of Evidence Level III Laryngoscope , 134:2678–2683, 2024
Cerebrovascular Reactivity Is Reduced in Postmenopausal Women with a History of Hypertensive Pregnancy Disorders
Johnson, Maja C, Johnson, Christopher P., Miller, Virginia M. , Harvey, Ronée E. , Johnson, Christopher P, Joyner, Michael J. , Barnes, Jill N.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.998.1 Get It

Women who have experienced hypertensive pregnancy disorders (HPD) are at an increased risk for developing cardiovascular disease later in life, including fatal and non‐fatal stroke. Cerebrovascular reactivity is related to stroke in individuals with carotid artery disease, and it is possible that this measure may be altered in women with a history of HPD prior to overt cerebrovascular disease. It is unknown if cerebrovascular reactivity is altered in postmenopausal women decades after experiencing a hypertensive pregnancy. Therefore, the goal of this study was to determine if cerebral blood flow velocity and cerebrovascular reactivity are altered in women with a history of HPD in comparison to women with no history of HPD. We studied a cohort of postmenopausal women approximately 35 years after they experienced an HPD (n=27, age at testing: 58±1) and a group of age‐ and parity‐matched women with no history of HPD (n=30, age at testing: 59±1). We measured middle cerebral artery velocity (MCAv, via transcranial Doppler), continuous blood pressure (finger photoplethysmography), and end‐tidal CO 2 (nasal cannula) in these women at baseline (room air) and during stepped hypercapnia at 2, 4, and 6% inhaled CO 2 for 3 minutes at each condition. Women with a history of HPD had a higher body mass index than women without a history of HPD (29±1 vs. 26±1 kg/m 2 , respectively; p<0.05). At baseline and during 6% CO 2 , MCAv was lower in women with a history of HPD (baseline: 60±4 vs. 71±3 cm/s, respectively; 6% CO 2 : 82±6 vs. 99±5 cm/s, respectively; p<0.05 for both conditions) compared to women without a history of HPD. Cerebrovascular reactivity, the slope defining the association between MCAv and end‐tidal CO 2 across the entire breathing trial, was also lower in women with a history of HPD (2.0±0.2 vs. 2.7±0.2 cm/s/mmHg, respectively; p<0.05). Body mass index was not correlated with MCAv or cerebrovascular reactivity in either group (p>0.05). In conclusion, resting MCAv and cerebrovascular reactivity to CO 2 is lower in women with a history of HPD in comparison with women who have never experienced HPD. Our findings suggest that HPD may have long‐term effects on cerebrovascular regulation in women who have suffered from these conditions. Support or Funding Information NIH HL083947, NIA 1P50AG044170‐01, and CTSA UL1TR000135
Surgical Outcomes in Zenker Diverticula: A Multicenter, Prospective, Longitudinal Study
Howell, Rebecca J. , Johnson, Christopher , Allen, Jacqui , Altaye, Mekibib , Bayan, Semirra L. , Belafsky, Peter C. , Cervenka, Brian , deSilva, Brad W. , Dion, Gregory R. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Kasperbauer, Jan L. , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Mayerhoff, Ross , McKeon, Mallory , Piraka, Cyrus , Rosen, Clark A. , Wahab, Shaun A. , Wilson, Keith , Wright, Carter , Young, VyVy N. , Postma, Gregory N. , Collaborative, Prospective OUtcomes of Cricopharyngeal Hypertonicity (POUCH), Howell, Rebecca , Bayan, Semirra, Belafsky, Peter , deSilva, Brad , Dion, Greg , Ekbom, Dale , Friedman, Aaron D , Giliberto, John Paul , Kasperbauer, Jan , Krekeler, Brittany N , Kuhn, Maggie , Ma, Yue , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Tabangin, Meredith , Young, Vyvy , Bayan, Semirra , Amin, Milan R , Giliberto, John Paul , Guardiani, Elizabeth , Kwak, Paul E. , Tabangin, Meredith E. , Wilson, Keith, Wright, Carter, Collaborative, Prospective OUtcomes of Cricopharyngeal Hypertonicity (POUCH)

Mayo Clinic

The Laryngoscope | May 16, 2023 | Volume: 134 | Issue: 1 | Pages: 97-102

10.1002/lary.30753 | PMID 37191092 Get It

ObjectiveTo compare improvement in patient‐reported outcomes (PROM) in persons undergoing endoscopic and open surgical management of Zenker diverticula (ZD).MethodologyProspective, multicenter cohort study of all individuals enrolled in the Prospective OUtcomes of Cricopharyngeus Hypertonicity (POUCH) Collaborative who underwent surgery for ZD. Patient survey, radiography reports, and the 10‐item Eating Assessment Tool (EAT‐10) pre‐ and post‐procedure were abstracted from a REDCap database, which summarized means, medians, percentages, and frequencies of. Outcome based on operative intervention (endoscopic vs. open) was compared using t‐test, Wilcoxon rank sum test or chi‐square test, as appropriate.ResultsOne hundred and forty‐seven persons were prospectively followed. The mean age (SD) of the cohort was 68.7 (11.0). Overall, 66% of patients reported 100% improvement in EAT‐10; 81% of patients had greater than 75% improvement; and 88% had greater than 50% improvement. Endoscopic was used for n = 109 patients, and open surgical intervention was used for n = 38. The median [interquartile range, IQR] EAT‐10 percent improvement for endoscopic treatment was 93.3% [72, 100], and open was 100% [92.3, 100] (p = 0.05). The incidence of intraoperative complications was 3.7% for endoscopic and 7.9% for open surgical management. The median [IQR] in follow‐up was 86 and 97.5 days, respectively.ConclusionBoth endoscopic and open surgical management of ZD provide significant improvement in patient‐reported outcomes. The data suggest that open diverticulectomy may provide a modest advantage in symptomatic improvement compared to endoscopic management. The data suggest that the postoperative complication rate is higher in the open surgical group.Level of Evidence3 Laryngoscope, 134:97–102, 2024
Bilateral ureteroinguinal hernia into the scrotum repaired in a staged fashion
Beckermann, Jason , Giese, Drake, Rentzepis, Michael J., Johnson, Christopher , Wildenberg, Joseph C. , Rentzepis, Michael, Wildenberg, Joseph , Beckermann, Jason , Johnson, Christopher

Mayo Clinic

Journal of Surgical Case Reports | December 29, 2022 | Volume: 2022 | Issue: 12 | Pages: No page available

10.1093/jscr/rjac591 | PMID 36589685 Get It

Abstract Bilateral ureteroinguinal hernia is a rare presentation with only five cases previously presented in the literature. We describe a 60-year-old male who was diagnosed with large bilateral hernias extending into the scrotum containing redundant ureters. Both hernias were repaired in staged fashion with retrograde temporary ureteral stent placement and modified Lichtenstein technique. Follow-up computerized tomography imaging with &gt;5 years follow-up revealed intact repairs with no evidence of urinary obstruction.